Brought to you by 
BioInvent, Pfizer sign antibody deal
03 Jan 2021
Executive Summary
BioInvent International AB licensed Pfizer Inc. rights to develop and commercialize antibodies targeting an undisclosed number tumor-associated myeloid cells.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com